IL6R and congenital rubella syndrome: In a study of leukemic mice, monocytes were the main source of IL-1 and IL-6 during CRS, and inhibition of the IL-6 receptor (IL6R) with tocilizumab prevented CRS but did not affect neurotoxicity.